PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9372618-5 1997 Interestingly, genistein, a soy isoflavone and a tyrosine kinase inhibitor, was able to inhibit the induction of Mn-SOD activity and mRNA expression by TNF-alpha. Isoflavones 32-42 tumor necrosis factor Homo sapiens 152-161 9486255-3 1998 Time- and dose-dependent TNF-alpha-stimulated ICAM-1 and E-selectin upregulation and neutrophil adhesion each were suppressed by tyrosine kinase inhibitors, including genistein (200 microM), but not genistein, its isoflavone analog without tyrosine kinase inhibitory activity. Isoflavones 214-224 tumor necrosis factor Homo sapiens 25-34 34521933-6 2021 Moreover, at the mRNA level of genes associated with the early inflammatory response characteristic for Ps (CAMP, CCL20, DEFB4A, PIK3CA, S100A7, and S100A9) and key cellular signalling (MTORC1 and TFEB), we showed that this isoflavone attenuated the increased response of IL-17A- and TNF-alpha-related pathways. Isoflavones 224-234 tumor necrosis factor Homo sapiens 284-293 33806207-3 2021 This study evaluated the potential of isoflavones isolated from Maclura tricuspidata fruit to prevent TNF-alpha-induced skin inflammation in normal human dermal fibroblasts (HDFs). Isoflavones 38-49 tumor necrosis factor Homo sapiens 102-111 8945961-7 1996 We found that the isoflavone compound genistein (25 micrograms/ml) prevented the TNF-alpha-induced expression of PAI-1 and TF while also slightly counteracting the decrease in t-PA synthesis. Isoflavones 18-28 tumor necrosis factor Homo sapiens 81-90 34455600-0 2022 The efficacy of soy isoflavones combined with soy protein on serum concentration of interleukin-6 and tumor necrosis factor-alpha among postmenopausal women? Isoflavones 20-31 tumor necrosis factor Homo sapiens 102-129 34455600-3 2022 The present study aimed to summarize the effect of soy isoflavones and soy protein on circulating interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in postmenopausal women. Isoflavones 55-66 tumor necrosis factor Homo sapiens 123-150 34455600-3 2022 The present study aimed to summarize the effect of soy isoflavones and soy protein on circulating interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in postmenopausal women. Isoflavones 55-66 tumor necrosis factor Homo sapiens 152-161 33586244-0 2021 The effect of soy isoflavones and soy isoflavones plus soy protein on serum concentration of tumor necrosis factor-alpha? Isoflavones 38-49 tumor necrosis factor Homo sapiens 93-120 33586244-2 2021 In this study, we summarized the effect of soy isoflavones and soy isoflavones plus soy protein on serum concentration of tumor necrosis factor-alpha (TNF-alpha) among adult participants. Isoflavones 43-58 tumor necrosis factor Homo sapiens 122-149 33586244-2 2021 In this study, we summarized the effect of soy isoflavones and soy isoflavones plus soy protein on serum concentration of tumor necrosis factor-alpha (TNF-alpha) among adult participants. Isoflavones 43-58 tumor necrosis factor Homo sapiens 151-160 33586244-2 2021 In this study, we summarized the effect of soy isoflavones and soy isoflavones plus soy protein on serum concentration of tumor necrosis factor-alpha (TNF-alpha) among adult participants. Isoflavones 63-78 tumor necrosis factor Homo sapiens 122-149 33586244-2 2021 In this study, we summarized the effect of soy isoflavones and soy isoflavones plus soy protein on serum concentration of tumor necrosis factor-alpha (TNF-alpha) among adult participants. Isoflavones 63-78 tumor necrosis factor Homo sapiens 151-160 33586244-7 2021 The result of overall effect size indicated a non-significant effect in serum concentration of TNF-alpha following soy isoflavones intake (WMD = 0.2 pg/ml, 95% CI: -0.13, 0.53; p = .226) and the combination of soy isoflavones and soy protein intake (WMD = 0.02 pg/ml, 95% CI: -0.02, 0.06; p = .286). Isoflavones 119-130 tumor necrosis factor Homo sapiens 95-104 33586244-7 2021 The result of overall effect size indicated a non-significant effect in serum concentration of TNF-alpha following soy isoflavones intake (WMD = 0.2 pg/ml, 95% CI: -0.13, 0.53; p = .226) and the combination of soy isoflavones and soy protein intake (WMD = 0.02 pg/ml, 95% CI: -0.02, 0.06; p = .286). Isoflavones 115-130 tumor necrosis factor Homo sapiens 95-104 33586244-9 2021 In conclusion, the present systematic review and meta-analysis found insufficient evidence that soy isoflavones or the combination of soy isoflavones and soy protein significantly reduce serum concentration of TNF-alpha. Isoflavones 96-111 tumor necrosis factor Homo sapiens 210-219 33586244-9 2021 In conclusion, the present systematic review and meta-analysis found insufficient evidence that soy isoflavones or the combination of soy isoflavones and soy protein significantly reduce serum concentration of TNF-alpha. Isoflavones 134-149 tumor necrosis factor Homo sapiens 210-219 24875672-7 2014 Individuals with moderate-high (>1.48 mg/day, N = 65) vs. low-no (<1.48 mg/day, N = 150) isoflavone consumption had significantly higher tumor necrosis factor alpha (TNFalpha) post-LPS (AUC, P = 0.009). Isoflavones 95-105 tumor necrosis factor Homo sapiens 143-170 32814603-8 2020 Subgroup analysis illustrated a reduction in TNF-alpha in in parallel designed studies, at dosages >=100 mg of isoflavones, and in unhealthy subjects. Isoflavones 111-122 tumor necrosis factor Homo sapiens 45-54 32814603-9 2020 The present study showed that high doses of isoflavones in unhealthy subjects may yield beneficial effects on TNF-alpha. Isoflavones 44-55 tumor necrosis factor Homo sapiens 110-119 29679037-7 2018 Through in vitro experiments, we found that isoflavone extract can reduce IL-22, IL-17A, and TNF-alpha-induced MAPK, NF-kappaB, and JAK-STAT activation in normal human epidermal keratinocytes. Isoflavones 44-54 tumor necrosis factor Homo sapiens 93-102 29679037-8 2018 At the mRNA level, we determined that isoflavone extract attenuated the increased response of the TNF-alpha-, IL-17A-, and IL-22- related pathways. Isoflavones 38-48 tumor necrosis factor Homo sapiens 98-107 24875672-7 2014 Individuals with moderate-high (>1.48 mg/day, N = 65) vs. low-no (<1.48 mg/day, N = 150) isoflavone consumption had significantly higher tumor necrosis factor alpha (TNFalpha) post-LPS (AUC, P = 0.009). Isoflavones 95-105 tumor necrosis factor Homo sapiens 172-180 24631489-6 2014 Furthermore, both isoflavones significantly attenuated TNFalpha-dependent barrier disruption, thereby maintaining a high barrier resistance comparable to nonstressed cells. Isoflavones 18-29 tumor necrosis factor Homo sapiens 55-63 24062607-10 2013 Isoflavone led to a stronger descent of the concentration of ALP and a decrease of IL-6 and TNF-alpha level than placebo. Isoflavones 0-10 tumor necrosis factor Homo sapiens 92-101 24062607-11 2013 For climacteric women, soy isoflavone in the dose of 90 mg/day could improve some menopausal syndromes and was effective on increasing limb bone density, which maybe had the relationship with the levels of IL-6, TNF-alpha and ALP in serum. Isoflavones 27-37 tumor necrosis factor Homo sapiens 212-221 21907578-1 2011 It has been previously shown that some flavonoids inhibit NF-kappaB; however, the structure-activity relationships between chalcone, flavanone, flavone, and isoflavone derivatives and their TNFalpha induced NF-kappaB inhibitory effects on HCT116 human colon cancer cells have not yet been reported. Isoflavones 157-167 tumor necrosis factor Homo sapiens 190-198 24064732-3 2013 Here we report on the inhibitory effects of isoflavones such as genistein and daidzein on muscle atrophy caused by tumor necrosis factor (TNF)-alpha treatment. Isoflavones 44-55 tumor necrosis factor Homo sapiens 115-148 24064732-7 2013 Moreover, isoflavones significantly suppressed MuRF1 promoter activity and myotube atrophy induced by TNF-alpha in C2C12 myotubes. Isoflavones 10-21 tumor necrosis factor Homo sapiens 102-111 22191384-10 2012 CONCLUSION: Diet, physical exercise and a daily oral intake of soy isoflavones exerted a beneficial effect on the homeostatic model in postmenopausal women which was not related to significant changes in plasma leptin levels, despite a decrease in TNF-alpha, fat mass and Kupperman values. Isoflavones 67-78 tumor necrosis factor Homo sapiens 248-257 23109410-0 2012 Genistein and daidzein, typical soy isoflavones, inhibit TNF-alpha-mediated downregulation of adiponectin expression via different mechanisms in 3T3-L1 adipocytes. Isoflavones 36-47 tumor necrosis factor Homo sapiens 57-66 12105943-5 2002 The isoflavone genistein was an inhibitor of TNF-alpha, whereas daidzein induced TNF-alpha production. Isoflavones 4-14 tumor necrosis factor Homo sapiens 45-54 19082897-0 2009 Isoflavone genistein protects human vascular endothelial cells against tumor necrosis factor-alpha-induced apoptosis through the p38beta mitogen-activated protein kinase. Isoflavones 0-10 tumor necrosis factor Homo sapiens 71-98 19926933-0 2009 Suppressive effect of an isoflavone fraction on tumor necrosis factor-alpha-induced interleukin-8 production in human intestinal epithelial Caco-2 cells. Isoflavones 25-35 tumor necrosis factor Homo sapiens 48-75 19926933-2 2009 Among the soybean components, an isoflavone fraction (IFF) suppressed the TNF-alpha-induced IL-8 secretion by Caco-2 cells in a dose-dependent manner, whereas a soyasaponin fraction and soypeptide fraction had no significant effect on TNF-alpha-induced IL-8 secretion. Isoflavones 33-43 tumor necrosis factor Homo sapiens 74-83 15840745-0 2005 Decreased circulating levels of tumor necrosis factor-alpha in postmenopausal women during consumption of soy-containing isoflavones. Isoflavones 121-132 tumor necrosis factor Homo sapiens 32-59 15840745-2 2005 OBJECTIVE: This study determined the effect of soy rich in isoflavones on levels of TNF-alpha. Isoflavones 59-70 tumor necrosis factor Homo sapiens 84-93 15840745-7 2005 CONCLUSIONS: Isoflavones may be the active components in soy responsible for the decrease of TNF-alpha found in postmenopausal women during a soy diet. Isoflavones 13-24 tumor necrosis factor Homo sapiens 93-102 17237310-4 2007 Using static and flow-dependent monocyte adhesion assays, our data show that exposure of endothelial cells to biologically relevant concentrations of isoflavones inhibits subsequent TNF-alpha induced monocyte adhesion only during flow. Isoflavones 150-161 tumor necrosis factor Homo sapiens 182-191 16629226-0 2006 The isoflavone genistein inhibits LPS-stimulated TNFalpha, but not IL-6 expression in monocytes from hemodialysis patients and healthy subjects. Isoflavones 4-14 tumor necrosis factor Homo sapiens 49-57 15805228-5 2005 Using an in vitro flow assay, we report that genistein, a principal component of most isoflavone preparations, inhibits monocyte adhesion to cytokine (TNF-alpha)-stimulated human vascular endothelial cells at physiologically relevant concentrations (0-1 microM). Isoflavones 86-96 tumor necrosis factor Homo sapiens 151-160 12720581-4 2003 In a macrophage cell line (RAW 264.7) activated with interferon gamma plus lipopolysaccharide, both isoflavones were found to inhibit NO production and tumour necrosis factor alpha (TNF-alpha) secretion dose-dependently, but they did not affect mRNA levels for inducible nitric oxide synthase and cyclo-oxygenase-2. Isoflavones 100-111 tumor necrosis factor Homo sapiens 182-191 12720581-5 2003 Both isoflavones also dose-dependently decreased monocyte chemoattractant protein-1 secretion induced by TNF-alpha in human umbilical vein endothelial cells. Isoflavones 5-16 tumor necrosis factor Homo sapiens 105-114 11368927-0 2001 Soy isoflavone supplementation in healthy men prevents NF-kappa B activation by TNF-alpha in blood lymphocytes. Isoflavones 4-14 tumor necrosis factor Homo sapiens 80-89 11368927-6 2001 Additionally, we investigated the in vivo effect of soy isoflavone supplementation on NF-kappa B activation induced by TNF-alpha in vitro in peripheral blood lymphocytes of six healthy men. Isoflavones 56-66 tumor necrosis factor Homo sapiens 119-128 11368927-7 2001 We show that healthy male subjects receiving 50 mg isoflavone mixture (Novasoy) twice daily for 3 weeks are protected from TNF-alpha induced NF-kappa B activation. Isoflavones 51-61 tumor necrosis factor Homo sapiens 123-132